Skip to content
★ Sign in to follow
Jiangsu Canopus Wisdom Medical Technology Co.,Ltd. logo

Jiangsu Canopus Wisdom Medical Technology Co.,Ltd. Stock: price and insider trades · China

东星医疗

CN·Mcap CN¥2.5BHealth Care

No insider purchase over the last 90 days. The latest, by 龚爱琴, was filed 07 Jan 2025.

Jiangsu Canopus Wisdom Medical Technology Co.,Ltd.: what insiders have been doing

Jiangsu Canopus Wisdom Medical Technology Co.,Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SSE / SZSE (CSRC). No insider at Jiangsu Canopus Wisdom Medical Technology Co.,Ltd. has published a filing in the past twelve months. The most recent one dates from 7 January 2025.

Our records for Jiangsu Canopus Wisdom Medical Technology Co.,Ltd. go back to 2024, with 4 purchases and no sales on the open market in total.

In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.

Insider Decl.
4
Thresholds
n/a
Buy Volume
€31,861
4 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
魏建刚1 buy
龚爱琴1 buy

Since the insiders bought

  • Filed 07 Jan 2025 · 670 days ago · €1,143
    +18.9%
    Entry CN¥22.32 · Close at T+365 CN¥26.53
  • Filed 06 Jan 2025 · 671 days ago · €288
    +17.8%
    Entry CN¥22.20 · Close at T+365 CN¥26.16
  • Filed 27 Aug 2024 · 803 days ago · €14k
    +43.2%
    Entry CN¥19.47 · Close at T+365 CN¥27.88

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 20,468 of 26,912 companies
33.6
score / 100
Value
37
Quality
30
FCF yld1.5%
Earn yld-1.5%
EV/EBITDA·
ROE-1.7%
Gross mgn49%
Net mgn-9.8%
Debt/EBITDA7.5x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥25.08
Analyst consensus
·
Income statement
RevenueCN¥387.5M
Gross profitCN¥188.3M49% margin
EBITDACN¥15.7M4% margin
Net income-CN¥37.9M-8.9% margin
Valuation
P/Book1.1x
Beta0.69
Balance sheet & cash
Market capCN¥2.5B
Total debtCN¥118M
Free Cash FlowCN¥38M
Debt / Equity5%
Profitability & ownership
ROE-1.7%
ROA1.3%
% insiders45.2%
% institutions2.8%
Last declaration on 7 January 2025
Declarations4 total
  • ▲
    董秘,董事,高管Executives
    8,692 CNY20SZSE
    400 shares6.4% of flowA股XSHESZSE:173000008409096000
    Canonical exit: 7 Apr 2025 (T+90)
  • ▲
    董事,高管Executives
    2,170 CNY15SZSE
    100 shares100.0% of flowA股XSHESZSE:173000008405370050
    Canonical exit: 6 Apr 2025 (T+90)
  • ▲
    董事Executives
    109,041 CNY27SZSE
    5,700 shares100.0% of flowA股XSHESZSE:173000008022967840
    Canonical exit: 25 Nov 2024 (T+90)
  • ▲
    董秘,董事,高管Executives
    133,070 CNY15SZSE
    7,000 shares93.6% of flowA股XSHESZSE:173000008015000770
    Canonical exit: 24 Nov 2024 (T+90)

4 of 4 declarations

About Jiangsu Canopus Wisdom Medical Technology Co.,Ltd.

东星医疗 is a company specializing in the healthcare and pharmaceutical sector, listed on the XSHE market. It focuses on the development and provision of innovative medical solutions.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations